Table 3.
Univariate and multivariate analyses of clinical and treatment‐related factors associated with grade ≥ 2 mucositis
| Factors | Grade ≥ 2 mucositis in all patients (n = 60) | Grade ≥ 2 mucositis in matched cohort (n = 38) | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||
| n (%) | P‐value | HR (95% CI) | P‐value | n (%) | P‐value | HR (95% CI) | P‐value | |
| Age | ||||||||
| (Years, means ± SD) | 49.3 ± 14.0 | .684 | 49.3 ± 14.1 | .668 | ||||
| Gender | ||||||||
| Male | 47 (59.5%) | .473 | 29 (52.7%) | .616 | ||||
| Female | 13 (68.4%) | 9 (60%) | ||||||
| Performance status | ||||||||
| ECOG 0 or 1 | 59 (60.8%) | 1.000 | 38 (54.3%) | – | ||||
| ECOG 2 | 1 (100%) | – | ||||||
| Smoking history | ||||||||
| Yes | 33 (62.3%) | .951 | 17 (51.5%) | .582 | ||||
| No | 17 (63%) | 12 (60%) | ||||||
| AJCC stage | ||||||||
| I–III | 29 (52.7%) | .051 | 1 | .294 | 20 (45.5%) | .054 | 1 | .196 |
| IV | 31 (72.1%) | 1.649 (.648–4.196) | 18 (69.2%) | 2.079 (.686–6.303) | ||||
| GTV volume | ||||||||
| (cc, means ± SD) | 48.9 ± 27.5 | .010 | 1.015 (.995–1.036) | .133 | 40.2 ± 26.7 | .078 | 1.012 (.988–1.038) | .330 |
| Bilateral neck irradiation | ||||||||
| Yes | 58 (61.7%) | .640 | 36 (54.5%) | 1.000 | ||||
| No | 2 (50%) | 2 (50%) | ||||||
| RT modality | ||||||||
| HT only | 44 (69.8%) | .019 | 1 | .166 | 22 (62.9%) | .150 | 1 | .276 |
| HT/IMPT combination | 16 (45.7%) | .521 (.208–1.309) | 16 (45.7%) | .576 (.213–1.555) | ||||
Abbreviations: AJCC, American Joint Committee on Cancer; CCRT, concurrent chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; GTV, gross tumor volume; HT, helical tomotherapy; IMPT, intensity‐modulated proton therapy; LN, lymph node; RT, radiotherapy; SD, standard deviation.